We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+6.6%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$117M
AUM Growth
-$70.2M
(-38%)
Cap. Flow
-$66.2M
Cap. Flow
% of AUM
-56.76%
Top 10 Holdings %
Top 10 Hldgs %
55.08%
Holding
38
New
9
Increased
1
Reduced
19
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$12.1M |
| 2 |
Axsome Therapeutics
AXSM
|
+$6.13M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$4.54M |
| 4 |
Korro Bio
KRRO
|
+$3.63M |
| 5 |
EyePoint Inc
EYPT
|
+$3.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$8.99M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
+$8.03M |
| 3 |
Revolution Medicines
RVMD
|
+$7.41M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$6.76M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$6.04M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
1
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.3M | 10.58% |
+147,750
| New | +$12.1M |
|
|
2
Tarsus Pharmaceuticals
TARS
$2.61B
| $9.59M | 8.22% |
173,144
-148,754
| -46% | -$6.76M |
|
3
Insmed
INSM
$23.5B
| $7.9M | 6.77% |
114,360
-36,473
| -24% | -$2.63M |
|
|
4
Axsome Therapeutics
AXSM
$11.8B
| $5.64M | 4.84% |
+66,661
| New | +$6.13M |
|
5
Xenon Pharmaceuticals
XENE
$6.6B
| $5.07M | 4.35% |
129,291
-82,500
| -39% | -$3.41M |
|
6
CG Oncology
CGON
$6.34B
| $4.99M | 4.28% |
174,048
-89,218
| -34% | -$3.05M |
|
|
MRUS
7
DELISTED
Merus
MRUS
| $4.91M | 4.21% |
116,796
-91,448
| -44% | -$4.39M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $4.87M | 4.18% |
55,892
-50,188
| -47% | -$4.6M |
|
9
Janux Therapeutics
JANX
$992M
| $4.83M | 4.14% |
90,292
-18,519
| -17% | -$980K |
|
|
CNTA
10
DELISTED
Centessa Pharmaceuticals
CNTA
| $4.1M | 3.51% |
244,538
-65,076
| -21% | -$1.08M |
|
|
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
| $3.94M | 3.38% |
+87,629
| New | +$4.54M |
|
12
Geron
GERN
$924M
| $3.8M | 3.26% |
1,074,824
-256,229
| -19% | -$1.02M |
|
|
ALMS
13
Alumis Inc
ALMS
$3.65B
| $3.5M | 3% |
445,259
+26,843
| +6% | +$269K |
|
14
Praxis Precision Medicines
PRAX
$8.77B
| $3.46M | 2.97% |
44,982
-28,203
| -39% | -$2.04M |
|
15
Trevi Therapeutics
TRVI
$2.71B
| $3.22M | 2.76% |
781,489
-541,311
| -41% | -$1.73M |
|
16
Enliven Therapeutics
ELVN
$3.8B
| $3.19M | 2.73% |
141,710
-93,146
| -40% | -$2.41M |
|
|
17
Korro Bio
KRRO
$177M
| $2.69M | 2.31% |
+70,678
| New | +$3.63M |
|
18
Jasper Therapeutics
JSPR
$29.4M
| $2.62M | 2.24% |
122,424
-277,042
| -69% | -$5.77M |
|
|
19
EyePoint Inc
EYPT
$1.12B
| $2.59M | 2.22% |
+348,000
| New | +$3.24M |
|
|
WHWK
20
Whitehawk Therapeutics
WHWK
$192M
| $2.58M | 2.21% |
+817,939
| New | +$1.85M |
|
|
ATYR
21
aTyr Pharma
ATYR
$50M
| $2.53M | 2.17% |
+699,730
| New | +$2.12M |
|
|
ETNB
22
DELISTED
89bio
ETNB
| $2.49M | 2.13% |
+317,833
| New | +$2.62M |
|
23
Tyra Biosciences
TYRA
$1.91B
| $2.43M | 2.09% |
175,063
-95,012
| -35% | -$1.72M |
|
24
Dianthus Therapeutics
DNTH
$5.77B
| $2.32M | 1.99% |
+106,434
| New | +$2.74M |
|
|
DFTX
25
Definium Therapeutics
DFTX
$5.88B
| $2.3M | 1.97% |
330,275
-458,233
| -58% | -$3.15M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2024 Portfolio in Review
As of Q4 2024, Ally Bridge Group held 38 positions worth $117M, down 38% from $187M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Ally Bridge Group withdrew a net $66.2M in Q4 2024, closing 8 positions and reducing 19 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $8.99M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in Intra-Cellular Therapies Inc. worth $12.3M.
- Ally Bridge Group's largest Q4 2024 buy was Intra-Cellular Therapies Inc.: 147,750 shares worth $12.3M.
- Ally Bridge Group added most to Alumis Inc in Q4 2024, an estimated $269K increase.
- Ally Bridge Group's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $6.76M.
- Ally Bridge Group fully exited Sarepta Therapeutics in Q4 2024, selling an estimated $8.99M.
- Ally Bridge Group's ten largest holdings make up 55% of its $117M portfolio in Q4 2024.
- Ally Bridge Group opened 9 new positions and closed 8 in Q4 2024.
- Ally Bridge Group's portfolio value fell 38% quarter-over-quarter to $117M.
Based on Ally Bridge Group's 13F filing for Q4 2024, filed 14 Feb 2025.